Disease Modification in Psoriasis: Future Prospects for Long-Term Remission.

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Moderate-to-severe psoriasis patients can experience prolonged remission post-drug withdrawal.
• Modern biologics, like interleukin-23 inhibitors, are associated with these extended remissions.
• Psoriatic arthritis, a significant comorbidity, may be prevented or delayed by these therapies.

Purpose of the Study:

• To review evidence on disease modification in psoriasis.
• To discuss potential clinical and molecular markers for predicting or monitoring disease modification.

Main Methods:

• Literature review of current evidence on psoriasis disease modification.
• Analysis of studies on interleukin-23 inhibitors and long-term patient outcomes.
• Exploration of potential predictive biomarkers.

Main Results:

• A subset of patients shows sustained remission beyond drug half-lives.
• Interleukin-23 inhibitors may alter underlying disease mechanisms, not just symptoms.
• Prevention or delay of psoriatic arthritis is observed in some patients.

Conclusions:

• Psoriasis treatments, particularly biologics, may offer disease-modifying effects.
• Identifying markers for disease modification is crucial for personalized treatment.
• Further research is needed to validate and predict these long-term effects.